20 November 2020 - The new 100 mg/mL formulation will reduce infusion time by approximately 60%, lessening the burden on patients.
Alexion Pharmaceuticals today announced that the European Commission has approved the new 100 mg/mL intravenous formulation of Ultomiris (ravulizumab) for the treatment of two ultra-rare diseases – paroxysmal nocturnal hemoglobinuria and atypical haemolytic uraemic syndrome.